<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26370" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Osteitis Fibrosa Cystica</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Naji Rad</surname>
            <given-names>Sara</given-names>
          </name>
          <aff>Icahn School of Medicine at Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anastasopoulou</surname>
            <given-names>Catherine</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Barnett</surname>
            <given-names>Maxim J.</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Deluxe</surname>
            <given-names>Linda</given-names>
          </name>
          <aff>Elmhurst Hospital Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Naji Rad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maxim Barnett declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Linda Deluxe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26370.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Osteitis fibrosa cystica, often referred to as OFC, is a rare but clinically significant bone disorder characterized by profound skeletal changes resulting from excessive parathyroid hormone (PTH) activity. This condition is primarily associated with hyperparathyroidism, particularly in its severe and uncontrolled form, and is most commonly seen in patients with chronic kidney disease.&#x000a0;As PTH plays a pivotal role in regulating calcium levels in the body, its dysregulation can lead to a cascade of skeletal and systemic complications. OFC is characterized by the resorption of bone tissue, leading to the formation of cyst-like cavities within the bones and an increased risk of fractures, deformities, and metabolic abnormalities.&#x000a0;The incidence of this disorder has decreased significantly following earlier detection of hyperparathyroidism through routine screening of serum calcium in frequently asymptomatic patients.&#x000a0;Understanding the pathophysiology, clinical manifestations, diagnostic criteria, and management strategies for&#x000a0;OFC is essential for healthcare professionals in various specialties, as it plays a pivotal role in the comprehensive care of patients affected by this complex skeletal disorder. This activity reviews the evaluation and optimal management of&#x000a0;OFC and highlights the role of the&#x000a0;interprofessional team in detecting and treating this condition in affected individuals.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify risk factors for the development and progression of osteitis fibrosa cystica in at-risk patient populations.</p></list-item><list-item><p>Select appropriate laboratory studies and, if indicated, imaging modalities&#x000a0;to evaluate&#x000a0;patients with osteitis fibrosa cystica.</p></list-item><list-item><p>Implement evidence-based treatment protocols for osteitis fibrosa cystica, including vitamin D supplementation, parathyroidectomy, or pharmacological interventions as indicated.</p></list-item><list-item><p>Collaborate with&#x000a0;an interprofessional team&#x000a0;to develop a comprehensive care plan for patients with osteitis fibrosa cystica, addressing primary and underlying conditions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26370&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26370">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26370.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Osteitis fibrosa cystica (OFC), a disorder of skeletal bone, is a pathognomonic yet infrequent finding of late-stage hyperparathyroidism. OFC is also referred to by the eponym 'von Recklinghausen Disease of the Bone,' highlighting the description by Friedrich Daniel von Recklinghausen in 1891; however, it is noteworthy that the first description of this phenomenon was&#x000a0;posed 27 years earlier in 1864 by Gerhard Engel.&#x000a0;Moreover, it was not until 1904 that von Askanasy demonstrated the correlation between OFC and the parathyroid glands.<xref ref-type="bibr" rid="article-26370.r1">[1]</xref></p>
        <p>OFC translates to 'cystic bone destruction' and occurs in the setting of chronic and sustained overactivity of the parathyroid glands with excessive release of parathyroid hormone (PTH) acting upon osseous tissues.<xref ref-type="bibr" rid="article-26370.r2">[2]</xref>&#x000a0;While once a common manifestation of hyperparathyroidism, OFC is now a rare occurrence in Western countries, especially in the United States, largely due to the introduction of auto analyzers in the 1970s-1980s, allowing earlier detection of even asymptomatic hyperparathyroidism and resultant prevention of late-stage&#x000a0;osseous manifestations.<xref ref-type="bibr" rid="article-26370.r3">[3]</xref><xref ref-type="bibr" rid="article-26370.r4">[4]</xref>&#x000a0;</p>
        <p>OFC may occur in any setting of sustained elevation of PTH, including primary, secondary, and tertiary hyperparathyroidism. Excessive osteoclast activation manifests as but is not limited to, bone swelling, pain, deformity, depleted bone mineral density, and fractures. Lesions may be either single or multiple and are&#x000a0;characterized histologically&#x000a0;as "brown tumors" due to repetitive microtrauma and microfractures, leading to&#x000a0;hemosiderin deposition; however, this is a misnomer, as they do not harbor neoplastic potential.<xref ref-type="bibr" rid="article-26370.r5">[5]</xref>&#x000a0;While&#x000a0;OFC may be progressive alongside continued activation of the parathyroid glands and stimulation of the osteoclasts, treatment of the underlying disorder of hyperparathyroidism, most often&#x000a0;with a parathyroidectomy, is curative with ultimate resolution of the disease.<xref ref-type="bibr" rid="article-26370.r6">[6]</xref></p>
      </sec>
      <sec id="article-26370.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>OFC may occur in any setting of&#x000a0;PTH overproduction, including primary (both normocalcaemic and hypercalcemic), secondary,&#x000a0;and tertiary hyperparathyroidism.<xref ref-type="bibr" rid="article-26370.r7">[7]</xref><xref ref-type="bibr" rid="article-26370.r8">[8]</xref><xref ref-type="bibr" rid="article-26370.r9">[9]</xref><xref ref-type="bibr" rid="article-26370.r10">[10]</xref>&#x000a0;Notably,&#x000a0;OFC is a frequent manifestation of end-stage renal disease.<xref ref-type="bibr" rid="article-26370.r11">[11]</xref>&#x000a0;Regarding primary hyperparathyroidism, this is most commonly due to a sporadic adenoma in up to 85% of cases and less frequently associated with parathyroid carcinoma, however, both have been associated with OFC.&#x000a0;In the setting of carcinoma, one must distinguish&#x000a0;OFC from osseous metastases.<xref ref-type="bibr" rid="article-26370.r12">[12]</xref>&#x000a0;Additionally, genetic causes of primary hyperparathyroidism, including hyperparathyroidism jaw-tumor syndrome, familial isolated hyperparathyroidism, and multiple endocrine neoplasia, have all been associated with OFC. OFC has also been demonstrated in the case of pseudohypoparathyroidism, which occurs with elevated&#x000a0;PTH in the absence of hypercalcemia, mostly due to variable end-organ resistance.<xref ref-type="bibr" rid="article-26370.r13">[13]</xref>&#x000a0;As a final consideration,&#x000a0;OFC has been demonstrated to occur in cases of elevated PTH-related peptide (where the PTH level will be suppressed), such as ectopic production by adult T-cell leukemia.<xref ref-type="bibr" rid="article-26370.r14">[14]</xref></p>
      </sec>
      <sec id="article-26370.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Following routine detection of asymptomatic hypercalcemia with a subsequent diagnosis of hyperparathyroidism through the addition of the auto analyzer in clinical practice, the prevalence of hyperparathyroidism has increased, however, concurrent &#x02018;severe&#x02019; disease has decreased reciprocally.<xref ref-type="bibr" rid="article-26370.r2">[2]</xref>&#x000a0;While&#x000a0;OFC was once a common manifestation of hyperparathyroidism with a prevalence of approximately 69%, the prevalence in the United States has significantly decreased over the last 50 years to approximately 5% with primary hyperparathyroidism and 1.5% with secondary hyperparathyroidism.<xref ref-type="bibr" rid="article-26370.r4">[4]</xref><xref ref-type="bibr" rid="article-26370.r15">[15]</xref>&#x000a0;In contrast, developing nations continue to demonstrate an excessive prevalence of OFC and&#x000a0;other late sequelae of hyperparathyroidism due to the&#x000a0;unavailability of earlier detection.<xref ref-type="bibr" rid="article-26370.r16">[16]</xref></p>
        <p>Brown tumors, the distinctive histopathological finding of localized OFC, appear to be more common in persons older than 50 years, in addition to the female gender, for which it is hypothesized that there is an element of hormonal involvement for its development.<xref ref-type="bibr" rid="article-26370.r5">[5]</xref>&#x000a0;Alternative theories, as to why&#x000a0;the development of OFC, as well as the presence of parathyroid carcinoma, in which case the&#x000a0;OFC occurs in about 90% of patients compared to a mere 5% of patients with benign disease that, may be due to the higher serum&#x000a0;PTH associated with carcinomas.<xref ref-type="bibr" rid="article-26370.r17">[17]</xref><xref ref-type="bibr" rid="article-26370.r18">[18]</xref></p>
      </sec>
      <sec id="article-26370.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Sustained overproduction of&#x000a0;PTH leads to the sequelae of hyperparathyroidism, including OFC. The most commonly involved body areas include the pelvic girdle, mandible (but not maxilla, which is an uncommon location), clavicle, ribs, and ends of long bones; however, with the progression of the disease, no bone is spared from possible involvement.<xref ref-type="bibr" rid="article-26370.r19">[19]</xref></p>
        <p>Excessive&#x000a0;PTH binds to osteoblasts, which leads to the expression of receptor activator of nuclear factor kappa-&#x003b2; ligand (RANKL), which itself attaches to receptor activator of nuclear factor kappa-&#x003b2; (RANK) on osteoclast precursors, allowing differentiation into osteoclasts and inhibition of osteoprotegerin expression. The osteoprotegerin functions to bind to RANKL and prevent interaction with RANK.<xref ref-type="bibr" rid="article-26370.r20">[20]</xref><xref ref-type="bibr" rid="article-26370.r21">[21]</xref>&#x000a0;With the activation of osteoclasts, bone resorption commences through cortical destruction and fibrous cyst formation. Brown tumors are formed with the replacement of the marrow with vascularized fibrous tissue and repetitive microfractures and microhemorrhages, producing the clinical manifestations of pain, weakening, swelling, deformities, and risk for fracture.<xref ref-type="bibr" rid="article-26370.r22">[22]</xref><xref ref-type="bibr" rid="article-26370.r23">[23]</xref></p>
      </sec>
      <sec id="article-26370.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Brown tumors, also known as osteoclastomas, are the classic histological manifestation of OFC&#x000a0;and represent localized disease.<xref ref-type="bibr" rid="article-26370.r24">[24]</xref>&#x000a0;Microscopically,&#x000a0;OFC is notable foh osteoclast and osteoblast activity within the osseous tissue alongside hemosiderin-laden macrophages and cyst formation from rapid bone loss and subsequent hemorrhage, granulation, and fibrous tissue replenishment within the marrow.<xref ref-type="bibr" rid="article-26370.r25">[25]</xref></p>
      </sec>
      <sec id="article-26370.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>History taking should begin with assessing the disease duration, previous treatments received, and previous records to review the severity of the hyperparathyroidism. It is important to note that patients with&#x000a0;OFC have likely had a long duration of hyperparathyroidism or have severe disease, and in addition to musculoskeletal manifestations, may demonstrate other end-organ complications, including renal (kidney stones, failure, polyuria), abdominal (pancreatitis, ulceration, nausea, vomiting, constipation), and psychiatric disturbances (fatigue, lethargy, disturbances with memory, depression).</p>
        <p>Regarding musculoskeletal manifestations, it is essential to assess for a history of pathological fractures, review previous imaging of the skeleton (looking&#x000a0;for osteopenia or osteoporosis), ask the patient about pain, and investigate for deformities of the bones, including bowing of the long bones. Moreover, depressed reflexes can be associated&#x000a0;with hypercalcemia and can be reproduced upon physical examination. While any bone can be affected in OFC, most commonly, it is the mandible, clavicle, pelvic girdle, and ribs, which should prompt consideration of the presence of OFC.<xref ref-type="bibr" rid="article-26370.r19">[19]</xref> Physical examination should also include a head and neck exam, assessing for a palpable mass over the anterior neck consistent with a parathyroid adenoma or carcinoma.</p>
      </sec>
      <sec id="article-26370.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Due to the infrequent occurrence of OFC, routine radiological screening in the absence of clinical suspicion (such as&#x000a0;in asymptomatic patients) is not warranted.<xref ref-type="bibr" rid="article-26370.r1">[1]</xref><xref ref-type="bibr" rid="article-26370.r26">[26]</xref>&#x000a0;As discussed in the previous section, a concerning history and physical examination are justifiable for further radiological assessment. Classical radiological descriptions of&#x000a0;OFC include a "salt-and-pepper" skull, subperiosteal bone resorption of the second and third fingers at the proximal and middle phalanges, involvement of the distal clavicle, as well as widespread brown tumors and bone cysts.<xref ref-type="bibr" rid="article-26370.r27">[27]</xref>&#x000a0;Generalized decreased mineral density of the bone (osteopenia) may be noted,&#x000a0;with cortical bone being involved more commonly than cancellous bone.<xref ref-type="bibr" rid="article-26370.r6">[6]</xref>&#x000a0;A bone biopsy can be considered and may differentiate&#x000a0;OFC from a bone tumor.<xref ref-type="bibr" rid="article-26370.r28">[28]</xref>&#x000a0;A caveat, however, is the risk of seeding of the cancerous cells in the setting of malignancy.</p>
        <p>Laboratory findings of hyperparathyroidism include hypercalcemia (albeit occasionally may demonstrate normocalcemia), elevated, or inappropriately normal, PTH, hypophosphatemia, and elevated alkaline phosphatase (the latter correlating with the degree of overt OFC).<xref ref-type="bibr" rid="article-26370.r8">[8]</xref>&#x000a0;In the setting of suppressed PTH, this should lead to the consideration of hypercalcemia of malignancy, for which the underlying cancerous tissue must be identified, in addition to consultation with an oncologist. The presence of hyperparathyroidism in a young patient or a patient with a strong family history should prompt consideration of a genetic cause, with a referral to a geneticist.</p>
        <p>In the setting of OFC, parathyroidectomy is the treatment of choice,&#x000a0;leading to the resolution of disease; however, this requires surgical planning prior to the procedure. As a result, patients may undergo an ultrasound scan of the neck to identify the parathyroid glands, in addition to a sestamibi scan that would assist in confirming the location and potentially identifying any ectopic glandular tissue.&#x000a0;</p>
      </sec>
      <sec id="article-26370.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of&#x000a0;OFC involves targeting the underlying cause of hyperparathyroidism. In the setting of primary hyperparathyroidism, it will require parathyroidectomy, for which resolution of the brown tumors is expected, rendering surgery redundant.&#x000a0;Local surgical procedures (such as incisions) may be performed at sites of&#x000a0;OFC in the setting of&#x000a0;functional problems, most notably persistent deformity, pathological fractures, and discomfort. Infrequent case reports have noted the usage of corticosteroids to decrease the tumor size should it persist post-parathyroidectomy.<xref ref-type="bibr" rid="article-26370.r25">[25]</xref>&#x000a0;Treatment of&#x000a0;OFC has also been shown with refrigerated transplantation of osseous tissue, demonstrating resolution of the lesions on follow-up after curettage and packing of the cavity with refrigerated bone chips.<xref ref-type="bibr" rid="article-26370.r29">[29]</xref>&#x000a0;</p>
        <p>It is also imperative to manage the underlying renal disease, especially in the setting of secondary hyperparathyroidism, and to treat co-existent vitamin D deficiency, which can lead to more severe musculoskeletal complications. It has also been demonstrated that oral vitamin D can lead to the regression of brown tumors and symptoms of OFC.<xref ref-type="bibr" rid="article-26370.r30">[30]</xref></p>
      </sec>
      <sec id="article-26370.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>As&#x000a0;OFC is rather uncommon, it is infrequently considered in the differential diagnosis, however, it is nonetheless an important differential diagnosis as its recognition would help avoid unnecessary invasive testing and procedures.<xref ref-type="bibr" rid="article-26370.r27">[27]</xref>&#x000a0;The presence of hypercalcemia and lytic bone lesions leads to a consideration of hypercalcemia of malignancy versus&#x000a0;OFC from hyperparathyroidism itself. This is best differentiated by the measurement of PTH, which is depressed in hypercalcemia of malignancy but elevated (or inappropriately normal) in OFC.&#x000a0;OFC can occasionally mimic metastatic parathyroid carcinoma, albeit this is very uncommon.<xref ref-type="bibr" rid="article-26370.r9">[9]</xref>&#x000a0;</p>
        <p>Further differential diagnoses include giant bone marrow tumors, solid aneurysmal bone cysts, and a giant cell reparative granuloma.<xref ref-type="bibr" rid="article-26370.r1">[1]</xref><xref ref-type="bibr" rid="article-26370.r27">[27]</xref>&#x000a0;The distinction between the aforementioned conditions may pose challenges.<xref ref-type="bibr" rid="article-26370.r28">[28]</xref> While bone scintigraphy can assess areas of increased uptake associated with hyperparathyroidism, this may be falsely positive for malignancy, osteomalacia, and infection.&#x000a0;Similarly, a positron emission tomography scan cannot distinguish between benign and malignant osseous neoplasms.&#x000a0;Furthermore, the histological assessment may demonstrate overlap between these conditions, leading to difficulty in differentiation and accurate diagnosis.<xref ref-type="bibr" rid="article-26370.r1">[1]</xref></p>
      </sec>
      <sec id="article-26370.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Untreated&#x000a0;OFC parallels the severity of hyperparathyroidism, and treatment requires resolution of the underlying hyperparathyroidism. Although&#x000a0;OFC is a dire condition associated with suffering, the prognosis is&#x000a0;favorable if the underlying disease driving the hyperparathyroidism can be controlled. OFC typically resolves following parathyroidectomy in the setting of primary hyperparathyroidism, rendering surgical management of the brown tumors unnecessary. It has been demonstrated that bone remineralization of the skeleton occurs, with the recovery of osteopenia and healing of the brown tumors upon radiological and histological assessment, in addition to clinical improvement expressed by both the patient and objective examination.<xref ref-type="bibr" rid="article-26370.r3">[3]</xref></p>
      </sec>
      <sec id="article-26370.s12" sec-type="Complications">
        <title>Complications</title>
        <p>OFC, if left untreated, may lead to perpetual pain, musculoskeletal weakness, deformities, erosions, bowing of the bones, cyst development, and fractures. Furthermore, with OFC, patients are likely to have other complications of hyperparathyroidism present, including nephrolithiasis, renal failure, fatigue, abdominal pain, psychiatric disturbances, and polyuria.<xref ref-type="bibr" rid="article-26370.r27">[27]</xref></p>
      </sec>
      <sec id="article-26370.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>In the United States,&#x000a0;OFC is an infrequent manifestation (&#x0003c;5%) of hyperparathyroidism, occurring in those with longer duration and more severe disease. Hypercalcemia is routinely detected most commonly in asymptomatic patients during routine medical check-ups prior to end-organ manifestations; however, in developing countries where routine check-ups are not available,&#x000a0;OFC and other manifestations of hyperparathyroidism are more frequently seen. It is essential to consider this uncommon complication to recognize the symptoms of bone pain, swelling, deformity, and weakness in cases of severe and untreated disease.</p>
      </sec>
      <sec id="article-26370.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Early diagnosis of hyperparathyroidism is vital to limit end-organ damage and prevent complications such as OFC. Due to the infrequent nature of this phenomenon, however, routine radiological screening is not indicated in the absence of suspicion for OFC. Patient-centered education is a valuable tool for which the&#x000a0;demonstration of symptoms concerning&#x000a0;OFC (such as bone pain, weakness, deformities, and swelling) should prompt urgent evaluation to prevent untoward bone complications. Apart from the endocrinology department, other healthcare professionals are likely to be in contact with such patients,&#x000a0;emphasizing the importance of early recognition of signs and symptoms of&#x000a0;OFC.&#x000a0;</p>
        <p>Enhancing patient-centered care and improving outcomes for individuals with OFC requires a collaborative approach involving physicians, advanced care practitioners, nurses, pharmacists, and other healthcare professionals.&#x000a0;Clinicians&#x000a0;must possess a deep understanding of OFC, its pathophysiology, diagnostic methods, and treatment options. This includes proficiency in interpreting bone scans, laboratory results, and monitoring bone health. Collaborative teams should develop individualized care plans based on patient-specific factors, including the severity of OFC, comorbid conditions, and patient preferences. Advocacy for patients' needs, including referrals to specialists, physical therapy, or counseling services, is a shared responsibility among the interprofessional team. By fostering strong&#x000a0;multidisciplinary collaboration, healthcare professionals can provide patient-centered care that addresses the unique challenges OFC poses. This approach enhances patient safety, improves outcomes, and optimizes the overall care experience for individuals with this rare bone disorder.&#x000a0;</p>
      </sec>
      <sec id="article-26370.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26370&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26370">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/osteitis-fibrosa-cystica-von-recklinghausen-disease-of-the-bone/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26370">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26370/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26370">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26370.s16">
        <title>References</title>
        <ref id="article-26370.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misiorowski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bilezikian</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Osteitis Fibrosa Cystica.</article-title>
            <source>JBMR Plus</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>e10403</fpage>
            <pub-id pub-id-type="pmid">32995697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bilezikian</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Primary hyperparathyroidism: pathophysiology and impact on bone.</article-title>
            <source>CMAJ</source>
            <year>2000</year>
            <month>Jul</month>
            <day>25</day>
            <volume>163</volume>
            <issue>2</issue>
            <fpage>184</fpage>
            <page-range>184-7</page-range>
            <pub-id pub-id-type="pmid">10934983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanitcharoenkul</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Singsampun</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Unnanuntana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sirinvaravong</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Osteitis Fibrosa Cystica and pathological fractures-the classic but neglected skeletal manifestation of primary hyperparathyroidism: a case report.</article-title>
            <source>BMC Musculoskelet Disord</source>
            <year>2021</year>
            <month>May</month>
            <day>14</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>443</fpage>
            <pub-id pub-id-type="pmid">33990191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Crea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Traini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oragano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bellantone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raffaelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Are brown tumours a forgotten disease in developed countries?</article-title>
            <source>Acta Otorhinolaryngol Ital</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>410</fpage>
            <page-range>410-5</page-range>
            <pub-id pub-id-type="pmid">23349562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalapala</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Keerthi Sai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Babburi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Venigalla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pinisetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kotti</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ganipineni</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>An Endocrine Jaw Lesion: Dentist Perspective in Diagnosis.</article-title>
            <source>Case Rep Dent</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>2582038</fpage>
            <pub-id pub-id-type="pmid">27974979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bandeira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cusano</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Cassibba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Bilezikian</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Bone disease in primary hyperparathyroidism.</article-title>
            <source>Arq Bras Endocrinol Metabol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>553</fpage>
            <page-range>553-61</page-range>
            <pub-id pub-id-type="pmid">25166047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berthod</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Osteitis Fibrosa Cystica.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Mar</month>
            <day>12</day>
            <volume>382</volume>
            <issue>11</issue>
            <fpage>e15</fpage>
            <pub-id pub-id-type="pmid">32160666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frame</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Foroozanfar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Normocalcemic primary hyperparathyroidism with osteitis fibrosa.</article-title>
            <source>Ann Intern Med</source>
            <year>1970</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>253</fpage>
            <page-range>253-7</page-range>
            <pub-id pub-id-type="pmid">5454261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yousif</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Birkeland</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>A Young Man With Hypercalcemia.</article-title>
            <source>JAMA Otolaryngol Head Neck Surg</source>
            <year>2017</year>
            <month>Mar</month>
            <day>01</day>
            <volume>143</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-312</page-range>
            <pub-id pub-id-type="pmid">27684299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selvi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cakarer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanakol</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guler</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Keskin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Brown tumour of the maxilla and mandible: a rare complication of tertiary hyperparathyroidism.</article-title>
            <source>Dentomaxillofac Radiol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-8</page-range>
            <pub-id pub-id-type="pmid">19114425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baracaldo</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Iampornpipopchai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fogel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubinstein</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Facial disfigurement due to osteitis fibrosa cystica or brown tumor from secondary hyperparathyroidism in patients on dialysis: A systematic review and an illustrative case report.</article-title>
            <source>Hemodial Int</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>583</fpage>
            <page-range>583-92</page-range>
            <pub-id pub-id-type="pmid">25828738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mizamtsidi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nastos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mastorakos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vassiliou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gazouli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palazzo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, management, histology and genetics of sporadic primary hyperparathyroidism: old knowledge with new tricks.</article-title>
            <source>Endocr Connect</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>R56</fpage>
            <page-range>R56-R68</page-range>
            <pub-id pub-id-type="pmid">29330338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scandola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lucchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mazzanti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Turchi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[A case of pseudohypoparathyroidism with osteitis fibrosa cystica].</article-title>
            <source>Minerva Pediatr</source>
            <year>1977</year>
            <month>Nov</month>
            <day>03</day>
            <volume>29</volume>
            <issue>34</issue>
            <fpage>2047</fpage>
            <page-range>2047-51</page-range>
            <pub-id pub-id-type="pmid">593239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumagai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsurumoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shindo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Majima</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arima</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Osteitis fibrosa cystica generalizata with adult T-cell leukaemia: a case report.</article-title>
            <source>Br J Haematol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>107</volume>
            <issue>4</issue>
            <fpage>892</fpage>
            <page-range>892-4</page-range>
            <pub-id pub-id-type="pmid">10606900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glushko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Banjar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Nahal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colmegna</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Brown tumor of the pelvis.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>82</volume>
            <issue>12</issue>
            <fpage>799</fpage>
            <page-range>799-800</page-range>
            <pub-id pub-id-type="pmid">26651887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sathyakumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cherian</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>TV</given-names>
              </name>
            </person-group>
            <article-title>Impact of curative surgery on bone in a patient with osteitis fibrosa cystica of primary hyperparathyroidism.</article-title>
            <source>BMJ Case Rep</source>
            <year>2016</year>
            <month>Mar</month>
            <day>30</day>
            <volume>2016</volume>
            <pub-id pub-id-type="pmid">27030464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jervis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Osteolytic lesions: osteitis fibrosa cystica in the setting of severe primary hyperparathyroidism.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>May</month>
            <day>28</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">28554885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Givi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Parathyroid carcinoma.</article-title>
            <source>Clin Oncol (R Coll Radiol)</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>498</fpage>
            <page-range>498-507</page-range>
            <pub-id pub-id-type="pmid">20510594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santhanam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chandrasekaran</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Multifocal Brown Tumor: A Case of Primary Hyperparathyroidism.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2021</year>
            <month>Aug</month>
            <day>01</day>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>e166</fpage>
            <page-range>e166-e167</page-range>
            <pub-id pub-id-type="pmid">31977659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sakata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pfleger</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Bencsik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Halloran</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Bikle</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Nissenson</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>PTH differentially regulates expression of RANKL and OPG.</article-title>
            <source>J Bone Miner Res</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-44</page-range>
            <pub-id pub-id-type="pmid">14969393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cianferotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cetani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Bone disease in primary hyperparathyrodism.</article-title>
            <source>Ther Adv Musculoskelet Dis</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>357</fpage>
            <page-range>357-68</page-range>
            <pub-id pub-id-type="pmid">23024712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Livolsi</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Bandeira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caldas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bilezikian</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Tc99m-sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>86</volume>
            <issue>11</issue>
            <fpage>5138</fpage>
            <page-range>5138-41</page-range>
            <pub-id pub-id-type="pmid">11701666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vilanilam</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Nikpanah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vo</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Kearns</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Osteitis Fibrosa Cystica: Brown Tumors of Hyperparathyroidism and End-Stage Renal Disease.</article-title>
            <source>Radiographics</source>
            <year>2023</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>e220211</fpage>
            <pub-id pub-id-type="pmid">37079460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flores</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Caridade</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Secondary Hyperparathyroidism Presenting as a Brown Tumor: A Case Report and Review of the Literature.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>e33820</fpage>
            <pub-id pub-id-type="pmid">36819315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garla</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Akhtar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Salim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Subauste</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Osteitis fibrosa cystica masquerading as bone neoplasm.</article-title>
            <source>BMJ Case Rep</source>
            <year>2018</year>
            <month>May</month>
            <day>07</day>
            <volume>2018</volume>
            <pub-id pub-id-type="pmid">29735505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misiorowski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Czajka-Oraniec</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kochman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zgliczy&#x00144;ski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bilezikian</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism.</article-title>
            <source>Endocrine</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>380</fpage>
            <page-range>380-385</page-range>
            <pub-id pub-id-type="pmid">28900835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasser</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Medawar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Younan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abboud</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trak-Smayra</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Osteitis fibrosa cystica mimicking bone tumor, a case report.</article-title>
            <source>BMC Musculoskelet Disord</source>
            <year>2021</year>
            <month>May</month>
            <day>25</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>479</fpage>
            <pub-id pub-id-type="pmid">34034731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>QM</given-names>
              </name>
            </person-group>
            <article-title>A patient with femoral osteitis fibrosa cystica mimicking bone neoplasm: a case report.</article-title>
            <source>BMC Musculoskelet Disord</source>
            <year>2022</year>
            <month>Apr</month>
            <day>04</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>322</fpage>
            <pub-id pub-id-type="pmid">35379205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Follow-up study of the use of refrigerated homogenous bone transplants in orthopaedic operations : Philip D. Wilson MD (1886-1969). The 3rd president of the AAOS 1934.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>466</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-36</page-range>
            <pub-id pub-id-type="pmid">18196370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26370.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zahed</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Birbari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El-Hajj Fuleihan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Regression of skeletal manifestations of hyperparathyroidism with oral vitamin D.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>91</volume>
            <issue>7</issue>
            <fpage>2480</fpage>
            <page-range>2480-3</page-range>
            <pub-id pub-id-type="pmid">16608887</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
